Skip to main content
logo
Avience Biomedicals Limited (NSE:AVIENCE)
India flag India · Delayed Price · Currency is INR
346.80
+10.45 (3.11%)
At close: Sep 10, 2026

Avience Biomedicals Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
525.06525.06452.36239.64109.26101.48
Revenue Growth
417.43%16.07%88.77%119.32%7.68%795.59%
Gross Profit
236.75236.75181.1683.2831.3726.35
Operating Income
140.05140.05111.5238.212.2211.21
Net Income
87.5387.5372.9121.527.767.13
Earnings Per Share
21.7121.7119.226.552.915.30
EPS Growth
309.87%12.97%193.39%125.41%-45.14%-30.40%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
29.3429.3449.373.572.450.25
Total Debt
289.35289.35221.58151.3126.5724.88
Net Cash (Debt)
-260-260-172.22-147.74-24.12-24.64
Net Cash Growth
------
Net Cash Per Share
-64.49-64.49-45.39-44.98-9.04-18.31

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
59.0659.0633.349.8515.87-19.63
Capital Expenditures
-134.49-134.49-93.08-38.81-16.88-8.69
Free Cash Flow
-75.42-75.42-59.75-28.96-1.01-28.31
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
45.09%45.09%40.05%34.75%28.71%25.97%
Operating Margin
26.67%26.67%24.65%15.94%11.18%11.05%
Pretax Margin
23.74%23.74%21.81%12.35%8.78%9.48%
Profit Margin
16.67%16.67%16.12%8.98%7.10%7.02%
FCF Margin
-14.37%-14.37%-13.21%-12.08%-0.92%-27.90%